Financial reports
10-K
2023 FY
Annual report
7 Mar 24
10-Q
2023 Q3
Quarterly report
9 Nov 23
10-Q
2023 Q2
Quarterly report
10 Aug 23
10-Q
2023 Q1
Quarterly report
11 May 23
10-K
2022 FY
Annual report
7 Mar 23
10-Q
2022 Q3
Quarterly report
10 Nov 22
10-Q
2022 Q2
Quarterly report
11 Aug 22
10-Q
2022 Q1
Quarterly report
12 May 22
10-K
2021 FY
Annual report
8 Mar 22
10-Q
2021 Q3
Quarterly report
15 Nov 21
Current reports
8-K
Optinose Provides Corporate Update on XHANCE Launch and Outlook and Announces Preliminary First Quarter 2024 XHANCE Net Revenue of $14.9 million
25 Apr 24
8-K
XHANCE Approved by FDA as First and Only Medication Indicated for Treatment of Adults with Chronic Rhinosinusitis without Nasal Polyps
15 Mar 24
8-K
Entry into a Material Definitive Agreement
14 Mar 24
8-K
Entry into a Material Definitive Agreement
8 Mar 24
8-K
Optinose Reports Fourth Quarter and Full Year 2023 Financial Results
7 Mar 24
8-K
Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant
23 Feb 24
8-K
Entry into a Material Definitive Agreement
21 Dec 23
8-K
Optinose Announces 3-Month Extension of FDA Review Period for the Supplemental New Drug Application for XHANCE
6 Dec 23
8-K
Optinose Reports Third Quarter 2023 Financial Results
9 Nov 23
8-K
Optinose Reports Second Quarter 2023 Financial Results
10 Aug 23
Registration and prospectus
S-8
Registration of securities for employees
7 Mar 24
S-3
Shelf registration
10 Aug 23
S-8
Registration of securities for employees
7 Mar 23
424B5
Prospectus supplement for primary offering
23 Nov 22
424B5
Prospectus supplement for primary offering
21 Nov 22
S-8
Registration of securities for employees
8 Mar 22
D
$4M in equity / options / securities to be acquired, sold $4M, 2 investors
30 Nov 21
424B5
Prospectus supplement for primary offering
18 Nov 21
424B5
Prospectus supplement for primary offering
15 Nov 21
S-3
Shelf registration
11 Aug 21
Proxies
DEF 14A
Definitive proxy
1 May 23
PRE 14A
Preliminary proxy
21 Apr 23
DEFA14A
Additional proxy soliciting materials
26 Apr 22
DEF 14A
Definitive proxy
26 Apr 22
DEFA14A
Additional proxy soliciting materials
28 Apr 21
DEF 14A
Definitive proxy
28 Apr 21
DEFA14A
Additional proxy soliciting materials
27 May 20
DEF 14A
Definitive proxy
29 Apr 20
DEF 14A
Definitive proxy
24 Apr 19
DEF 14A
Definitive proxy
25 Apr 18
Other
EFFECT
Notice of effectiveness
18 Aug 23
CORRESP
Correspondence with SEC
15 Aug 23
UPLOAD
Letter from SEC
15 Aug 23
CT ORDER
Confidential treatment order
25 Oct 21
EFFECT
Notice of effectiveness
1 Sep 21
CORRESP
Correspondence with SEC
23 Aug 21
UPLOAD
Letter from SEC
18 Aug 21
SEC STAFF
SEC staff action: Order
2 Apr 21
SEC STAFF
SEC staff action: Order
5 Mar 21
CT ORDER
Confidential treatment order
20 Mar 19
Ownership
SC 13G/A
Rosalind Advisors, Inc.
25 Apr 24
4
Anthony J Krick
19 Mar 24
4
Michael F Marino III
19 Mar 24
4
Ramy A Mahmoud
19 Mar 24
4
Anthony J Krick
29 Feb 24
4
Paul Jr. Spence
29 Feb 24
4
Michael F Marino III
29 Feb 24
4
Ramy A Mahmoud
29 Feb 24
SC 13G/A
Rosalind Advisors, Inc.
22 Feb 24
SC 13G/A
Rosalind Advisors, Inc.
14 Feb 24